To The Moon

Hey, this is Stocks_Pedia.

Here I would like to introduce you to some unfamiliar companies that you may probably haven't heard of, and hope it can be of some help to your investments.

The company I'm going to introduce this time is $Biogen(BIIB)$.

It went public on 20th September 1991.

[Company Profile]

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment ofneurological diseasesto patients worldwide.

[History & Events]

1978: Biogen was founded in Geneva as Biotechnology Geneva by several prominent biologists.

2003: Biogen merged with San Diego, California-based IDEC Pharmaceuticals.

2006: Biogen announced it would acquire cancer specialist, Conforma Therapeutics for $250 million.

2007: Biogen announced it would acquire Syntonix Pharmaceuticals for up to $120 million, gaining Syntonix's lead product for hemophilia B as well as the technology for developing inhalable treatments.

2011: Biogen announced that its drug Fampyra received conditional marketing approval. Under the conditional approval, Biogen agrees to provide additional data on the long-term benefits and safety of Fampyra.

2012: Biogen announced its global collaboration agreement with Isis Pharmaceuticals to develop and research antisense drugs to treat neurological and neuromuscular diseases.

2015: Biogen announced that it would acquire Convergence Pharmaceuticals for up to $675 million.

2016: Biogen announced to spin off its hemophilia business, known as Bioverativ.

2017: Biogen announced that its drug Fampyra converted from conditional marketing authorization to standard marketing approval.

[Main Business Segments]

[Net Income & Total Revenue]

[Competitors]

$Herbalife(HLF)$

Metagenics

Neo Life

$Usana Health Sciences(USNA)$